Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
French Innovative Leukemia Organisation
Massachusetts General Hospital
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Servier
Servier
Servier
National Cancer Institute (NCI)
Servier
National Cancer Institute (NCI)
M.D. Anderson Cancer Center